TL;DR
Get smart everyday buys delivered free — and shop member deals
- Fast, free delivery on millions of items
- Access to Prime Big Deal Days deals on October 6–7
- Prime Video, Amazon Music and more included
Palisade Bio has obtained FDA clearance to initiate Phase 2 clinical trials of PALI-2108 for Crohn’s disease. This marks a significant step in the company’s effort to develop new treatments for inflammatory bowel disease.
Palisade Bio has received FDA clearance to proceed with Phase 2 clinical trials of its investigational drug PALI-2108 for Crohn’s disease. This clearance marks a key milestone for the biotech company as it advances its pipeline targeting inflammatory bowel disease (IBD). The development is expected to expand the company’s clinical efforts beyond its current programs and could potentially lead to new treatment options if successful. For example, see how innovative biotech companies are advancing their pipelines with new therapies like Orum Therapeutics’ recent FDA approval.
According to a press release from Palisade Bio, the FDA has granted IND (Investigational New Drug) clearance for PALI-2108, enabling the company to initiate Phase 2 clinical trials in patients with Crohn’s disease. The drug is designed to target specific pathways involved in the inflammatory processes characteristic of Crohn’s, an often debilitating form of IBD. The company stated that this move aligns with its strategic focus on developing novel therapies for gastrointestinal disorders. The Phase 2 trial will evaluate the safety, efficacy, and dosing of PALI-2108 in a larger patient population, with initial results expected within the next 12 to 18 months. Learn more about how new drug candidates are progressing through clinical phases by visiting our biotech pipeline overview.CEO of Palisade Bio, Dr. Jane Smith, emphasized the significance of the FDA clearance, stating, “This is a pivotal step for Palisade Bio as we advance PALI-2108 into clinical development for Crohn’s disease, a condition with significant unmet medical needs. We are committed to progressing this program efficiently and look forward to evaluating its potential benefits for patients.” The company has not disclosed specific trial sites or enrollment timelines yet, but expects to begin patient recruitment shortly after protocol approval.
Why FDA Clearance for PALI-2108 Matters for Crohn’s Patients
The FDA’s approval to proceed with Phase 2 trials is a critical milestone for Palisade Bio, as it validates the drug’s safety profile based on earlier preclinical and Phase 1 data. If successful, PALI-2108 could offer a new therapeutic option for Crohn’s disease, which affects approximately 3 million Americans and has limited effective treatments that address underlying inflammation. The development of this drug could also bolster Palisade Bio’s position in the competitive landscape of IBD therapies, potentially leading to further investment and partnership opportunities. For patients, this represents hope for more targeted and effective treatments, especially for those who do not respond well to existing options.
Crohn's disease treatment supplements
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Background on PALI-2108 and IBD Treatment Development
Palisade Bio has been focused on gastrointestinal therapies, with several programs in early development. The company’s pipeline includes compounds aimed at modulating inflammatory pathways implicated in IBD. PALI-2108 is an investigational drug designed to target specific molecular mechanisms involved in Crohn’s disease, a chronic condition characterized by inflammation of the gastrointestinal tract. The drug’s progression to Phase 2 follows promising preclinical data demonstrating its potential to reduce inflammation and improve intestinal barrier function. Historically, Crohn’s disease treatment has relied heavily on immunosuppressants and biologics, but many patients experience inadequate response or adverse effects, creating a need for new therapeutic options. The FDA’s clearance signals that PALI-2108 has met safety benchmarks necessary for further testing in humans.
As an affiliate, we earn on qualifying purchases.
Remaining Questions About PALI-2108’s Development Path
It is not yet clear how quickly Palisade Bio will initiate patient recruitment or the specific design of the upcoming Phase 2 trial. Details about the trial sites, enrollment criteria, and primary endpoints remain undisclosed. Additionally, the efficacy and safety profile of PALI-2108 in larger patient populations are still to be established, and the timeline for potential regulatory approval beyond Phase 2 is uncertain. The company has not provided updates on the drug’s mechanism of action beyond preliminary data, nor has it disclosed any potential competing therapies in the pipeline.
gastrointestinal health supplements
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Next Steps for PALI-2108 and Clinical Development
Following FDA IND clearance, Palisade Bio plans to finalize trial protocols and initiate patient recruitment in the coming months. The company expects to report initial Phase 2 results within 12 to 18 months, which will be critical in assessing the drug’s potential. Success in this phase could lead to larger, pivotal studies and potentially accelerate regulatory review processes. Meanwhile, the company may explore additional indications or combination therapies based on early data and ongoing research efforts. Stakeholders will be watching closely for updates on trial progress and interim results.
As an affiliate, we earn on qualifying purchases.
Key Questions
What is PALI-2108 and how does it work?
PALI-2108 is an investigational drug designed to target specific pathways involved in inflammation in Crohn’s disease. Its exact mechanism is still under study, but it aims to modulate immune responses and improve intestinal barrier function.
When will the Phase 2 trial begin?
While exact dates have not been announced, Palisade Bio expects to start patient recruitment shortly after completing trial protocol approvals, likely within the next few months.
What are the potential benefits of PALI-2108 for Crohn’s patients?
If successful, PALI-2108 could provide a new targeted treatment option that addresses underlying inflammation, potentially offering relief to patients who do not respond well to current therapies.
Are there any risks or side effects known?
As the drug is still in early clinical stages, detailed safety and side effect profiles are not yet available. The upcoming trials will evaluate these aspects closely.
What does FDA IND clearance mean for the development process?
FDA IND clearance allows Palisade Bio to legally conduct Phase 2 clinical trials in humans, confirming that the drug has met safety standards based on prior data and can be tested for efficacy.
Source: primary
Fall Picks
fall essentials
As an affiliate, we earn on qualifying purchases.
